This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

About Zinforo

About Zinforo

OverviewExtended spectrum coverage


Adult & adolescent dosingNeonatal & paediatric dosing
Efficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric Safety
Clinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE study
Support & Resources

Support & Resources

Videos & case studiesVideos

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: High clinical cure rate and evidence of rapid response in CAPClinical cure rates: FOCUS 1 and 2

FOCUS 1 and 2 trials: Two Phase III, randomised, double-blind, multinational, multicentre, non-inferiority trials comparing Zinforo (600 mg IV every 12 hours, adjusted for moderate renal impairment) vs ceftriaxone (1 g IV every 24 hours)2

Zinforo has proven efficacy in CAP patients…

Clinical cure rates: FOCUS 1 and 2||

… and high early clinical response rates at Day 4, including for Streptococcus pneumoniae infections.3‡Zinforo delivers high cure rates in patients with severe disease, risk factors for difficult-to-treat infections and a number of comorbidities2
Explore More Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice.  Access CAP patient profiles  Loading To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study. View CAPTURE study data  Loading

||The lower limit of the 95% CI was above –10%, which met the predefined criteria for non-inferiority.7 Zinforo was well tolerated with a safety profile similar to that of ceftriaxone.7

Zinforo may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for Zinforo.

*CrCL 31–50 mL/min.2

Shown not to be statistically significant.3

§ Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2

**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1


CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; FOCUS, CeFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalised patients; MITTE, modified intent-to-treat efficacy; PORT, Pneumonia Patient Outcomes Research Team. NS, non significant 

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)

Great Britain

Zinforo 600 mg powder for concentrate for solution for infusion

Northern Ireland

Zinforo 600 mg powder for concentrate for solution for infusion 


ZINFORO. Summary of Product CharacteristicsFile TM, et al. Clin Infect Dis 2010;51:1395–405Eckburg P, et al. Infect Dis Clin Pract 2012;51:1395–405Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7Korczowski B et al, Paediatr Inf Dis J 2016 35 e239-47
PP-ZFO-GBR-0224. September 2021
Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials

View tolerability profile  Loading
Explore the outcomes of the other Zinforo Phase III clinical trials in patients with CAP and cSSTIZinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1,4-6​​​​​​​​​​​​​​

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2023 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021